ARTICLE | Company News
Abbisko builds combination strategy with China rights to X4's mavorixafor
July 17, 2019 12:02 AM UTC
Abbisko has licensed Greater China rights to X4’s mavorixafor, which the Shanghai-based company plans to use to develop a pipeline of combination therapies.
The deal, for which financial terms are not disclosed, gives Abbisko Therapeutics Co. Ltd. exclusive rights to develop and commercialize the CXCR4 antagonist in China, Taiwan, Hong Kong and Macao for oncology indications...